Dr Stuver on How to Approach pcPTCL-NOS Treatment Decision-Making

“The first step is to actually understand what [pcPTCL-NOS] is because this is a rare disease. Having a very thorough pathology review is paramount to picking the right treatment approach.”

Robert Stuver, MD, an assistant attending physician at Memorial Sloan Kettering Cancer Center, discussed primary cutaneous peripheral T-cell lymphoma, not otherwise specified [pcPTCL-NOS], and data for the disease, which were presented at the 6th World Congress for Cutaneous Lymphomas.

More specifically, Stuver overviewed how to approach treatment strategies for patients with this rare disease in addition to laying out which factors are most important to weigh in day-to-day clinical practice and what the common outcomes are for patients with pcPTCL-NOS.

Stuver began by pointing out that treatment decision-making for pcPTCL-NOS begins with assessing how aggressive the disease is behaving within patients in general. He then pointed out different scenarios with pcPTCL-NOS that would warrant different approaches, like patients who are ill and need to get better immediately, or in comparison, for those with indolent-behaving disease. Before arriving at either conclusion, Stuver pointed out that first, it is essential for clinicians to understand what pcPTCL-NOS is and the fundamentals of the disease. Obtaining thorough pathology reviews is paramount to discovering the optimal treatment approach for patients with pcPTCL-NOS, he said. Beyond thorough pathology reviews, once clinicians have confirmed pcPTCL-NOS diagnoses, monitoring factors like disease aggressiveness, disease location, and patient comorbidities are helpful in further assessing treatment, he added.

Stuver then discussed how pcPTCL-NOS typically acts in patients, pointing out that the disease commonly behaves aggressively. Importantly, Stuver highlighted how patients with localized pcPTCL-NOS experienced improved outcomes in comparison with those who had multifocal disease. Ultimately, the differences in outcomes for these patients is helpful in better understanding pcPTCL-NOS, he concluded.